148 related articles for article (PubMed ID: 7692455)
1. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study.
Altstaedt HO; Berzewski B; Breddin HK; Brockhaus W; Bruhn HD; Cachovan M; Diehm C; Dörrler J; Franke CS; Gruss JD
Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):573-8. PubMed ID: 7692455
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with peripheral arterial occlusive disease Fontaine stage III and IV with intravenous iloprost: an open study in 900 patients.
Staben P; Albring M
Prostaglandins Leukot Essent Fatty Acids; 1996 May; 54(5):327-33. PubMed ID: 8832761
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease.
Loosemore TM; Chalmers TC; Dormandy JA
Int Angiol; 1994 Jun; 13(2):133-42. PubMed ID: 7525794
[TBL] [Abstract][Full Text] [Related]
4. Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group.
Beischer W; Dembski JC; Gruss JD; Hofgärtner F; Horsch A; Horsch S; Kuhlmann HW; Loose DA; Mietaschk A; Schwilden ED; Spengel F; Spitzer W; Staben P; Stallkamp B; Stürzebecher CS; Tokhi M; von Bilderling P
Vasa; 1998 Feb; 27(1):15-9. PubMed ID: 9540427
[TBL] [Abstract][Full Text] [Related]
5. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost.
Balzer K; Bechara G; Bisler H; Clevert HD; Diehm C; Heisig G; Held K; Mahfoud Y; Mörl H; Rücker G
Int Angiol; 1991; 10(4):229-32. PubMed ID: 1724669
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV.
Creutzig A; Lehmacher W; Elze M
Vasa; 2004 Aug; 33(3):137-44. PubMed ID: 15461065
[TBL] [Abstract][Full Text] [Related]
7. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group.
Eur J Vasc Endovasc Surg; 2000 Oct; 20(4):358-62. PubMed ID: 11038148
[TBL] [Abstract][Full Text] [Related]
8. Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease.
Blardi P; de Lalla A; Pieragalli D; De Franco V; Meini S; Ceccatelli L; Auteri A
Prostaglandins Other Lipid Mediat; 2006 Sep; 80(3-4):175-82. PubMed ID: 16939882
[TBL] [Abstract][Full Text] [Related]
9. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
Arosio E; Sardina M; Prior M; De Marchi S; Zannoni M; Bianchini C
Eur Rev Med Pharmacol Sci; 1998; 2(2):53-9. PubMed ID: 10229559
[TBL] [Abstract][Full Text] [Related]
10. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training.
Scheffler P; de la Hamette D; Gross J; Mueller H; Schieffer H
Circulation; 1994 Aug; 90(2):818-22. PubMed ID: 8044953
[TBL] [Abstract][Full Text] [Related]
11. Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross-over study in patients with critical limb ischemia.
Schellong S; Altmann E; von Bilderling P; Rudofsky G; Waldhausen P; Rogatti W
Prostaglandins Leukot Essent Fatty Acids; 2004 Jun; 70(6):503-9. PubMed ID: 15120713
[TBL] [Abstract][Full Text] [Related]
12. Tolerance of Iloprost and results of treatment of chronic severe lower limb ischaemia in diabetic patients. A retrospective study of 64 consecutive cases.
Duthois S; Cailleux N; Benosman B; Lévesque H
Diabetes Metab; 2003 Feb; 29(1):36-43. PubMed ID: 12629446
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV.
Balzer K; Rogatti W; Rüttgerodt K
Vasa Suppl; 1989; 28():31-8. PubMed ID: 2609242
[TBL] [Abstract][Full Text] [Related]
14. [Medical therapy in critical lower limb ischemia when immediate revascularization is not feasible].
Melillo E; Nuti M; Buttitta F; Balbarini A
G Ital Cardiol (Rome); 2006 May; 7(5):317-35. PubMed ID: 16752515
[TBL] [Abstract][Full Text] [Related]
15. [Administration of prostaglandin E1 in diabetics and non-diabetic patients with severe Fontaine stage IIb arterial occlusive disease].
Hinderer S; Brachmann R; Nedder KH; Bucher J; Beischer W
Vasa; 1991; 20(2):100-8. PubMed ID: 1877328
[TBL] [Abstract][Full Text] [Related]
16. Effect of intravenous iloprost and alprostadil (PGE1) on peripheral resistance during femoro-distal reconstructions.
Krueger U; Scholz H; Heise M; Adeberg P; Petzold M; Zanow J; Karrenberg R
Int Angiol; 2000 Dec; 19(4):358-65. PubMed ID: 11305737
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a conservative treatment with iloprost in severe peripheral occlusive arterial disease (POAD). GISAP Study.
Int Angiol; 1994 Mar; 13(1):70-4. PubMed ID: 7521384
[TBL] [Abstract][Full Text] [Related]
18. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease.
Matsui K; Ikeda U; Murakami Y; Yoshioka T; Shimada K
Am Heart J; 2003 Feb; 145(2):330-3. PubMed ID: 12595852
[TBL] [Abstract][Full Text] [Related]
19. Effects of adjuvant PGE1 therapy following profundaplasty in patients with severe limb ischaemia. Early and long-term results.
Gruss JD
Vasa; 1997 May; 26(2):117-21. PubMed ID: 9174388
[TBL] [Abstract][Full Text] [Related]
20. Transcutaneous oxygen pressure as predictive parameter for ulcer healing in endstage vascular patients treated with spinal cord stimulation.
Claeys LG; Horsch S
Int Angiol; 1996 Dec; 15(4):344-9. PubMed ID: 9127776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
